Brain 17 Vienna

Conclusions



Long-term data from

EORTC 26951

and

RTOG 9402

suggest RT + PCV as standard of care for patients with

anaplastic glioma and 1p/19q co-deletion



NOA-04

data do not support an attempt to achieve

comparable outcomes with monochemotherapy in patients

with 1p/19q co-deleted tumors



RTOG 9802

long-term data suggest a benefit from RT/PCV

compared to RT alone in the entire cohort of grade II tumors



PFS and OS gain in the RTOG 9802 dataset is most

prominent in patients with oligodendroglial (=

1p/19q co-

deleted

?) tumors



Whether

PCV

can be replaced by

temozolomide

remains

unclear